Northwest Biotherapeutics (OTCMKTS:NWBO) stock is trading with moderate gains on Monday’s trading session.
As of 12:28, NWBO stock gained 3.68% at $1.69. The stock has traded 1.35 million shares, compared to its average volume of 2.04 million shares. The stock opened at $1.64 and moved in a range of $1.6200 – 1.7200.
NWBO Business Description
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer.
Its lead product, DCVax-L that is in Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.
|SHARES OUTSTANDING||842.29 M|
|SHARE FLOAT (%)||810.07 M (96.17%)|
|% HELD BY INSTITUTIONS||0.05|
Recent Stock Performance
|+/- EMA(20)||1.56 (+8.33%)|
|+/- SMA(50)||1.50 (+12.67%)|
|+/- SMA(200)||1.26 (+34.13%)|
|CCI20||59.3414||Buy||Chaikin Money Flow||0.0910||Buy|
|MACD||0.0598||Buy||Money Flow Index||63.5647||Buy|
|STOCH (14,3)||35.0000||Sell||STOCH RSI||0.0930||OverSold|